文献速递妇科

交界性卵巢肿瘤幸存者的生活质量:与早期卵巢癌幸存者及无癌人群的比较:一项基于人群的横断面PROFILES研究

Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
PubMed 文献 · Gynecol Oncol · 2024-08-02

该研究纳入83例交界性卵巢肿瘤(BOT)幸存者、88例仅手术治疗的Ⅰ期卵巢癌幸存者及82名按性别、年龄和教育匹配的无癌人群,采用EORTC QLQ-C30、EORTC QLQ-OV28及HADS量表评估健康相关生活质量(HRQoL)。多数HRQoL领域BOT幸存者与两组人群无显著差异,仅失眠少于早期卵巢癌幸存者、呼吸困难多于无癌人群(临床差异小)。

要点

  • BOT幸存者多数HRQoL领域与早期卵巢癌幸存者及无癌人群无显著差异。
  • BOT幸存者失眠显著少于早期卵巢癌幸存者。
  • BOT幸存者呼吸困难显著多于无癌人群,但临床差异小。

核心结论

  • 总体而言,BOT幸存者的HRQoL介于早期卵巢癌幸存者与无癌人群之间,但组间临床效应量多为微不足道。

研究设计与样本

  • 荷兰两项横断面、基于人群的研究邀请BOT与卵巢癌幸存者参与,纳入仅接受手术治疗的Ⅰ期卵巢癌幸存者。
  • 无癌人群随机样本按性别、年龄和教育与BOT幸存者样本匹配。
  • 研究1和研究2中无癌人群及BOT、卵巢癌幸存者完成EORTC QLQ-C30(3.0版)和EORTC QLQ-OV28。
  • 仅研究1中无癌人群及BOT、卵巢癌幸存者完成医院焦虑抑郁量表(HADS)。
  • 采用线性回归分析和效应量比较BOT幸存者与早期卵巢癌幸存者及一般人群。

主要发现

  • 多数HRQoL领域BOT幸存者与早期卵巢癌幸存者及无癌人群无显著差异。
  • BOT幸存者报告的失眠显著少于早期卵巢癌幸存者。
  • BOT幸存者报告的呼吸困难显著多于无癌人群,临床差异小。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study assessed the health-related quality of life (HRQo) of women surviving a borderline ovarian tumor (BOT) in comparison with early-stage ovarian cancer survivors treated surgically alone and with a matched cancer-free population. METHODS: Survivors of BOT and ovarian cancer were invited in two Dutch cross-sectional, population-based studies. Ovarian cancer survivors with tumor stage I who were treated surgically only were included. A random sample from the cancer-free population was matched on sex, age and education to the sample of BOT survivors. The EORTC QLQ-C30 (version 3.0) and the EORTC QLQ-OV28 were completed by the cancer-free population and the BOT and ovarian cancer survivors in study 1 and 2. The Hospital Anxiety and Depression Scale (HADS) was only completed by the cancer-free population and the survivors of BOT and ovarian cancer in study 1. BOT survivors were compared to early-stage ovarian cancer survivors and the general population using linear regression analyses and effect sizes regarding clinical importance. RESULTS: 83 BOT (42%), 88 early-stage ovarian cancer survivors (52%), and 82 women from the general population were included. In most HRQoL domains, BOT survivors were not significantly different from early-stage ovarian cancer survivors and the cancer-free population, except that BOT survivors reported significantly less insomnia than early-stage ovarian cancer survivors and more dyspnea than the cancer-free population (small clinical difference). CONCLUSION: In general, BOT survivors' HRQoL lies between the HRQoL of early-stage ovarian cancer survivors and of the cancer-free population, but clinical effect sizes between the groups were mostly only trivial.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. van der Eerden B, de Rooij BH, Schouten LJ, et al. Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study. Gynecol Oncol. 2024. PMID: 39096588. doi:10.1016/j.ygyno.2024.07.681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。